VOYDEYA 50 mg / 100 mg cpr pellic 50 mg 180(2x90)

7680693010031 CH-69301 L04AJ09 07.15.0.

No images available

Details

Product number
6930101
CPT
-
Packaging group
180 (2x90)
Unit
Tablette(n)
Composition
Filmtablette 50 mg: danicopanum 50 mg, hypromellosi acetas succinas, lactosum monohydricum 60.5 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), E 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 1.22 mg. Filmtablette 100 mg: danicopanum 100 mg, hypromellosi acetas succinas, lactosum monohydricum 121 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), E 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 2.44 mg.

Articles (1)

Voydeya 50 mg / 100 mg, Filmtabletten
Filmtabletten
180 (2x90)
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
05/04/2026
Professional SmPC
Français
05/04/2026
Professional SmPC
Italien
05/04/2026
Patient information leaflet
Allemand
17/03/2025
Patient information leaflet
Français
17/03/2025
Patient information leaflet
Italien
17/03/2025

Detailed composition

Substance Quantity Type Category
danicopanum
50.0 MG Substance Wirkstoff (Principe actif)
danicopanum
100.0 MG Substance Wirkstoff (Principe actif)
hypromellosi acetas succinas
- Substance HNIDK
hypromellosi acetas succinas
- Substance HNIDK
lactosum monohydricum
121.0 MG Substance HBESI
lactosum monohydricum
60.5 MG Substance HBESI
cellulosum microcristallinum
- Substance HNIDK
cellulosum microcristallinum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
carmellosum natricum conexum
- Substance HNIDK
natrii laurilsulfas
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
natrii laurilsulfas
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
silica colloidalis anhydrica
- Substance HNIDK
silica colloidalis anhydrica
- Substance HNIDK
magnesii stearas
- Substance HNIDK
magnesii stearas
- Substance HNIDK
poly(alcohol vinylicus)
- Substance HNIDK
poly(alcohol vinylicus)
- Substance HNIDK
E 171
- Substance FNIDK
E 171
- Substance FNIDK
macrogolum 3350
- Substance HNIDK
macrogolum 3350
- Substance HNIDK
talcum
- Substance HNIDK
talcum
- Substance HNIDK
natrium
- Substance HBESI
natrium
- Substance HBESI

Authorization holder

Alexion Pharma GmbH

6340 Baar

Authorization information

Swissmedic authorization number
69301
Drug name
Voydeya, Filmtabletten
Galenic form
FILM
ATC Code
L04AJ09
Authorization status
Z
Dispensation category
A
First authorization
30/04/2024
Authorization expiration date
29/04/2029
IT number
07.15.0.
Domain
Human medicine
Field of application
als Zusatztherapie zu Ravulizumab oder Eculizumab zur Behandlung bei klinisch relevanter extravaskulärer Hämolyse nach mindestens 6-monatiger Monotherapie mit einem C5-Inhibitor bei erwachsenen Patienten mit paroxysmaler nächtlicher Hämoglobinurie

Packaging details

Description (FR)
VOYDEYA 50 mg / 100 mg cpr pellic 50 mg 180(2x90)
Description (DE)
VOYDEYA 50 mg / 100 mg Filmtabl 50 mg 180(2x90) St
Market launch
30/04/2024
Narcotic (BTM)
No

Other packaging sizes

VOYDEYA cpr pellic 100 mg 180(2x90) pce
180 (2x90) TABL
GTIN: 7680693010048
View
Buy us a coffee Explore the data